These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 22002767)

  • 41. Making diagnosis of Pompe disease at a presymptomatic stage: to treat or not to treat?
    Laloui K; Wary C; Carlier RY; Hogrel JY; Caillaud C; Laforêt P
    Neurology; 2011 Aug; 77(6):594-5. PubMed ID: 21753173
    [No Abstract]   [Full Text] [Related]  

  • 42. A new assay for fast, reliable CRIM status determination in infantile-onset Pompe disease.
    Wang Z; Okamoto P; Keutzer J
    Mol Genet Metab; 2014 Feb; 111(2):92-100. PubMed ID: 24044919
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Enzyme replacement therapy in juvenile glycogenosis type II: a longitudinal study.
    Deroma L; Guerra M; Sechi A; Ciana G; Cisilino G; Dardis A; Bembi B
    Eur J Pediatr; 2014 Jun; 173(6):805-13. PubMed ID: 24395639
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adult Pompe disease: clinical manifestations and outcome of the first Greek patients receiving enzyme replacement therapy.
    Papadimas GK; Spengos K; Konstantinopoulou A; Vassilopoulou S; Vontzalidis A; Papadopoulos C; Michelakakis H; Manta P
    Clin Neurol Neurosurg; 2011 May; 113(4):303-7. PubMed ID: 21216089
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Quantification of muscle pathology in infantile Pompe disease.
    Schänzer A; Kaiser AK; Mühlfeld C; Kulessa M; Paulus W; von Pein H; Rohrbach M; Viergutz L; Mengel E; Marquardt T; Neubauer B; Acker T; Hahn A
    Neuromuscul Disord; 2017 Feb; 27(2):141-152. PubMed ID: 27927596
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The role of autophagy in the pathogenesis of glycogen storage disease type II (GSDII).
    Nascimbeni AC; Fanin M; Masiero E; Angelini C; Sandri M
    Cell Death Differ; 2012 Oct; 19(10):1698-708. PubMed ID: 22595755
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A beta-blocker, propranolol, decreases the efficacy from enzyme replacement therapy in Pompe disease.
    Han SO; Pope R; Li S; Kishnani PS; Steet R; Koeberl DD
    Mol Genet Metab; 2016 Feb; 117(2):114-9. PubMed ID: 26454691
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease).
    Raben N; Plotz P; Byrne BJ
    Curr Mol Med; 2002 Mar; 2(2):145-66. PubMed ID: 11949932
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Comprehensive Update on Late-Onset Pompe Disease.
    Labella B; Cotti Piccinelli S; Risi B; Caria F; Damioli S; Bertella E; Poli L; Padovani A; Filosto M
    Biomolecules; 2023 Aug; 13(9):. PubMed ID: 37759679
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers.
    Raben N; Fukuda T; Gilbert AL; de Jong D; Thurberg BL; Mattaliano RJ; Meikle P; Hopwood JJ; Nagashima K; Nagaraju K; Plotz PH
    Mol Ther; 2005 Jan; 11(1):48-56. PubMed ID: 15585405
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of enzyme replacement therapy on five patients with advanced late-onset glycogen storage disease type II: a 2-year follow-up study.
    Furusawa Y; Mori-Yoshimura M; Yamamoto T; Sakamoto C; Wakita M; Kobayashi Y; Fukumoto Y; Oya Y; Fukuda T; Sugie H; Hayashi YK; Nishino I; Nonaka I; Murata M
    J Inherit Metab Dis; 2012 Mar; 35(2):301-10. PubMed ID: 21984055
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impaired clearance of accumulated lysosomal glycogen in advanced Pompe disease despite high-level vector-mediated transgene expression.
    Sun B; Zhang H; Bird A; Li S; Young SP; Koeberl DD
    J Gene Med; 2009 Oct; 11(10):913-20. PubMed ID: 19621331
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Development of a clinical assay for detection of GAA mutations and characterization of the GAA mutation spectrum in a Canadian cohort of individuals with glycogen storage disease, type II.
    McCready ME; Carson NL; Chakraborty P; Clarke JT; Callahan JW; Skomorowski MA; Chan AK; Bamforth F; Casey R; Rupar CA; Geraghty MT
    Mol Genet Metab; 2007 Dec; 92(4):325-35. PubMed ID: 17723315
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Correction of glycogenosis type 2 by muscle-specific lentiviral vector.
    Richard E; Douillard-Guilloux G; Batista L; Caillaud C
    In Vitro Cell Dev Biol Anim; 2008; 44(10):397-406. PubMed ID: 18810562
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Glycogen Reduction in Myotubes of Late-Onset Pompe Disease Patients Using Antisense Technology.
    Goina E; Peruzzo P; Bembi B; Dardis A; Buratti E
    Mol Ther; 2017 Sep; 25(9):2117-2128. PubMed ID: 28629821
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years.
    Angelini C; Semplicini C; Ravaglia S; Bembi B; Servidei S; Pegoraro E; Moggio M; Filosto M; Sette E; Crescimanno G; Tonin P; Parini R; Morandi L; Marrosu G; Greco G; Musumeci O; Di Iorio G; Siciliano G; Donati MA; Carubbi F; Ermani M; Mongini T; Toscano A;
    J Neurol; 2012 May; 259(5):952-8. PubMed ID: 22081099
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease.
    Yi H; Sun T; Armstrong D; Borneman S; Yang C; Austin S; Kishnani PS; Sun B
    J Mol Med (Berl); 2017 May; 95(5):513-521. PubMed ID: 28154884
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Differential muscular glycogen clearance after enzyme replacement therapy in a mouse model of Pompe disease.
    Hawes ML; Kennedy W; O'Callaghan MW; Thurberg BL
    Mol Genet Metab; 2007 Aug; 91(4):343-51. PubMed ID: 17572127
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impaired autophagy contributes to muscle atrophy in glycogen storage disease type II patients.
    Nascimbeni AC; Fanin M; Masiero E; Angelini C; Sandri M
    Autophagy; 2012 Nov; 8(11):1697-700. PubMed ID: 22940840
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The role of immune tolerance induction in restoration of the efficacy of ERT in Pompe disease.
    Lacaná E; Yao LP; Pariser AR; Rosenberg AS
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):30-9. PubMed ID: 22253234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.